Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD) comes up as a prominent issue within the realm of chronic liver pathologies on a global scale. Hepatic insulin resistance (HIR) is an important aspect of metabolic dysfunction, serving as a primary driver of dysregulated glucose homeostasis. MAFLD and HIR, Type 2 diabetes mellitus-like in the liver, exhibit a complex interplay in the pathogenesis of metabolic disorders.
Objective: To evaluate the relationship between MAFLD and HIR by a systematic review.
Methods: To identify relevant studies published between January 1998 and July 2024, a comprehensive search was conducted across electronic databases, including PubMed, Web of Science, Scopus, Embase, and Cochrane Central. To ensure the inclusion of relevant and high-quality studies, inclusion and exclusion criteria were applied. The QUADAS-2, the systematic review ensured that potential biases were systematically identified, evaluated, and accounted for, enhancing the credibility and trustworthiness of the findings.
Results: After careful consideration, 8 studies were deemed to meet the stringent inclusion criteria and were subsequently selected for data extraction and analysis. These studies represented the core body of evidence that underpins the findings of this systematic review.
Conclusion: Our systematic review demonstrated a consistently demonstrated association between MAFLD and HIR. This association has been supported by findings from various studies, highlighting the significance of MAFLD as a potential risk factor for the development of HIR.
